Logo
x

Search

Subscribe Now

All Posts by Date

PharmaShots Weekly Snapshots (November 14 - 18 2022)

PharmaShots Weekly Snapshots (November 14 - 18 2022)

  • November 18, 2022
Iveric Bio’s Zimura (avacincaptad pegol) Receives the US FDA’s Breakthrough Therapy Designation for Geographic Atrophy

Iveric Bio’s Zimura (avacincaptad pegol) Receives the US FDA’s Breakthrough Therapy Designation for Geographic Atrophy

  • November 18, 2022
Evaxion Reports P-I/IIa Results of EVX-02 for the Treatment of Resected Melanoma

Evaxion Reports P-I/IIa Results of EVX-02 for the Treatment of Resected Melanoma

  • November 18, 2022
Immunic Reports P-II (EMPhASIS) Trial Results of IMU-838 (vidofludimus calcium) for the Treatment of Relapsing-Remitting Multiple Sclerosis

Immunic Reports P-II (EMPhASIS) Trial Results of IMU-838 (vidofludimus calcium) for the Treatment of Relapsing-Remitting Multiple...

  • November 18, 2022
Attralus Entered into Option and License Agreement with Ossianix to Deliver AT-04 for the Treatment of Neurodegenerative Disorders

Attralus Entered into Option and License Agreement with Ossianix to Deliver AT-04 for the Treatment of Neurodegenerative Disorders

  • November 18, 2022
BeiGene’s Brukinsa (zanubrutinib) Receives EC’s Approval for the Treatment Chronic Lymphocytic Leukemia

BeiGene’s Brukinsa (zanubrutinib) Receives EC’s Approval for the Treatment Chronic Lymphocytic Leukemia

  • November 18, 2022
Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.